Dapagliflozin combined with liraglutide has a synergistic effect in improving cardiac function and metabolic disorders in obese patients with HFpEF, with good safety, providing a more effective therapeutic strategy for clinical practice.
Key Findings
Results
The combination group showed a more significant decrease in N-terminal pro-B-type natriuretic peptide levels compared with both monotherapy groups after 24 weeks.
Retrospective study with 360 obese patients with HFpEF divided into 3 groups of 120 patients each
Groups were: combination (dapagliflozin + liraglutide), dapagliflozin monotherapy, and liraglutide monotherapy
Intervention duration was 24 weeks
Difference was statistically significant (P < .05)
Results
The combination group demonstrated greater improvement in 6-minute walk distance compared with both monotherapy groups.
6-minute walk distance was a primary endpoint
Improvement in the combination group was statistically greater than either monotherapy group (P < .05)
Intervention duration was 24 weeks across all groups
Results
The combination group achieved greater weight loss compared with the monotherapy groups.
Weight loss was assessed as a secondary metabolic endpoint
Difference was statistically significant (P < .05)
Liraglutide is a GLP-1 receptor agonist known to promote weight loss, and dapagliflozin is an SGLT2 inhibitor also associated with weight reduction
Results
Blood glucose control was better in the combination group than in either monotherapy group.
Blood glucose was assessed as a secondary metabolic endpoint
Difference was statistically significant (P < .05)
Both dapagliflozin and liraglutide have independent glucose-lowering mechanisms
Results
The incidence of major cardiovascular composite endpoints was lower in the combination group than in either monotherapy group.
Major cardiovascular composite endpoints were assessed as an outcome measure
Difference was statistically significant (P < .05)
Both monotherapy groups had higher incidence of major cardiovascular composite endpoints compared to the combination group
Results
The overall incidence of adverse events was similar across all three treatment groups.
Safety outcomes were assessed as secondary endpoints
No statistically significant difference in adverse event rates among the three groups (P > .05)
This indicates the combination therapy did not increase safety risks compared to monotherapy
Zhou G, Liu A, Hu X, Qi G, Zhang Y. (2026). Efficacy comparison of dapagliflozin combined with liraglutide versus monotherapy in obese patients with heart failure.. Medicine. https://doi.org/10.1097/MD.0000000000048123